Circular RNAs (circRNAs) are widely expressed in mammals and can regulate the development and progression of human tumors. has_circ_0015758 (circ-CFH) is an exon circRNA transcript from the GRCh37/hg19 fragment of chromosome 1 and is homologous to the protein-coding gene complement factor H (CFH). Currently, the function of circ-CFH in glioma remains unclear.
Background
Glioma, the most prevalent and aggressive tumor of the brain, arises from transformed glial cells [1] . The yearly incidence of gliomas is approximately 6 in 100 000 cases, and the disease is incurable [2] . Furthermore, the high recurrence rate of glioma is mainly because of its extensive growth, malignant behavior, and diffuse invasive characters [3] . Despite many clinical and pathological subtype studies, there remain few effective treatments for this disease. Therefore, there is an urgent need to find sensitive biomarkers and therapeutic targets for glioma, and this process requires insights into the precise mechanisms underlying glioma pathology [4] . Circular RNA (circRNA) is a novel type of noncoding RNA (ncRNA) [5] [6] [7] . CircRNAs form a covalently closed continuous loop structure without 5' or 3' tails, and their circular structure makes them resistant to RNase R activity and more stable [3, 8, 9] . They are derived from exons due to the process of back-splicing [10, 11] . CircRNAs are abundant and conserved in mammalian cells and have certain levels of tissue and cell specificity [12] [13] [14] . Generally, they can function as miRNA sponges and regulate gene transcription and expression [15, 16] . In particular, the circRNA-miRNA-mRNA signaling axis has been established to explore their functions [17] . Recent studies confirmed that circRNAs can regulate the development and progression of diseases, including cancer [18, 19] . An in-depth study revealed the function of circRNAs in tumor cell proliferation, migration, and invasion [15, 18, 20, 21] . Taken together, these findings indicate that circRNAs could be used as new diagnostic or predictive biomarkers and provide new effective disease treatments.
MicroRNAs, which are endogenous, noncoding, single-stranded RNAs of ~22 nucleotides, are involved in post-transcriptional gene regulation [22] [23] [24] [25] . MiRNAs can bind to the 3'UTR of the target mRNA to inhibit translation or stimulate mRNA degradation [26] [27] [28] [29] [30] [31] . In mammals, up to 2% of the genome codes for miRNA genes and ~60% of human protein-coding genes are targeted by miRNAs [32, 33] . Many studies have found that miRNAs can act as oncogenes or tumor suppressor genes by regulating cell proliferation, differentiation, angiogenesis, migration, and apoptosis [34] [35] [36] [37] [38] . MiRNA expression levels are usually altered and associated with pathological conditions [39, 40] . There are more distinct miRNAs expressed in the brain than in any other organ, implying a complex regulation network [41] [42] [43] .
In this study, we found a new circRNA, circ-CFH, that is derived from CFH gene exons and was upregulated in glioma tissue. Subsequently, the function and mechanism of circ-CFH were investigated. The antagonistic effect of circ-CFH on miR-149 was also confirmed. We revealed that circ-CFH plays an oncogenic role in glioma by functioning as a sponge of miR-149 to promote AKT1 expression.
Material and Methods

Tissue specimens
Thirty-one glioma tumor samples and paired adjacent normal tissues were obtained from Huai'an First People's Hospital. The study protocol was approved by the Research Ethics Committee of Huai'an First People's Hospital. In addition, written informed consent was obtained from all patients. The samples were immediately snap-frozen in liquid nitrogen and stored at -70°C before use.
Cell lines and cell culture
Primary normal human astrocytes (NHAs) were purchased from Sciencell Research Laboratories (Carlsbad, CA, USA). Human U87, A172, U251, TJ905, and U373 glioblastoma cell lines were purchased from the ATCC (Manassas, VA, USA). NHAs were cultured in Dulbecco's modified Eagle's medium (DMEM), but all glioma cell lines were cultured in DMEM-F12; both mediums were supplemented with 10% fetal bovine serum (FBS). The mediums and FBS were purchased from Invitrogen (Carlsbad, CA). All cells were maintained in a 37°C, 5% CO 2 incubator.
Cell transfections
Circ-CFH siRNA (SiCirc-CFH), negative control siRNA (SiNC), and circ-CFH mimic (circCFH) were obtained from RiboBio (Guangzhou, China). miRNA mimics (miR-149, miR-145, miR-155, and miR-183), a negative control mimic (NC), and an antisense oligonucleotide (miR-149 ASO) were obtained from GenePharma Co., Ltd. (Shanghai, China). The sequences of the mimics were as follows: miR-149, 5'-UCU GGC UCC GUG UCU UCA CUC CC-3'; miR-145, 5'-GUC CAG UUU UCC CAG GAA UCC CU-3'; miR-183, 5'-UGA AUU CUA CCA GUG CCA UAU U-3'; and miR-155, 5'-UUAAUGCUAAUCGUGAUAGGGGUU-3'. U373 and U251 cells were seeded in plates to 80% confluence and transfected with the constructs (50 nM) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA from the glioma samples and cultured cells was extracted using Trizol reagent (#9109, Takara, China). After quantitation, 5 µg of RNA was transcribed into cDNA using a cDNA synthesis kit (#6130, Takara, China). The reverse transcription products were mixed with TaqMan universal PCR master mix II, and real-time PCR was performed on the Applied Biosystems ® 7500 Real-Time PCR System. Relative expression levels were determined based on the 2 -DDCt method [44] . The mRNA expression of miR-145, miR-149, miR-155, and miR-183 was normalized to U6, and the mRNA expression of circ-CFH, AKT1, FOXM1, and LRIG2 was normalized to GAPDH. The specific primers used are listed as follows: Forward, 5'-CTC GCT TCG GCA CAT A-3', Reverse, 5'-AAC GAT TCA CGA ATT TGC GT-3' for U6; Forward, 5'-TGT GAG GGT TTC AGG AT-3', Reverse, 5'-CCA TGA GAA ATC TCA GGT GGA-3' for circ-CFH; Forward, 5'-CTG AAC GGG AAG CTC ACT GG-3', Reverse, 5'-AAA GTG GTC GTT GAG GGC AA-3' for GAPDH; Forward, 5'-CGC GCT CGA GCC CAG AGC AAT AAG CCA CAT-3', Reverse, 5'-GGT GTC GTG GAG TCG GCA ATT CAG TTG AG-3' for miR-145; Forward, 5'-TCT GGC TCC GTG TCT TCA CTC CC-3', Reverse, 5'-AGT GGT TGT TCT GCT CTC TGT GTC-3' for miR-149; Forward, 5'-CAG TCC CGG GTG CAG GCT GGA GAG TGT GAC-3', Reverse, 5'-GAT CGA TAT CCC TCA GGC AGT GAA AGG TGA TC-3' for miR-183; Forward, 5'-AGC AAG CGC GGG GAA CCA AGG-3', Reverse, 5'-TCC ATT GGG TGG GAG AGC CAA GG-3' for miR-155; Forward, 5'-CTG AGA TTG TGT CAG CCC TGG A-3', Reverse, 5'-CAC AGC CCG AAG TCT GTG ATC TTA-3' for AKT1; Forward, 5'-GGG CGC ACG GCG GAA GAT GAA-3', Reverse, 5'-CCA CTC TTC CAA GGG AGG GCT C-3' for FOXM1; and Forward, 5'-CAT GTG CCC TCA CTA CCA-3', Reverse, 5'-CTC CAG GAC CCG AGA ATA-3' for LRIG2. All primers were designed and purchased from Sangon (Shanghai, China).
CCK-8 assays
U373 and U251 cells were seeded onto 96-well plates and transfected. At 0 h, 12 h, 24 h, 48 h, and 72 h after transfection, 10 µl of CCK8 solution (CK04, Dojindo, Japan) was added to each well; 2 h later, the optical density value of each well was measured at 450 nm using a microplate reader (S28629, Fisher Scientific).
Colony formation assays
At 24 h after transfection, 5×10 3 U251 or U373 cells were evenly plated on 6-well plates and incubated for 10 days. The colonies were fixed in 10% formaldehyde and stained with 1% crystal violet solution for 5 min. After washing with PBS 5 times, visible colonies were imaged and counted.
Tumor xenograft growth assays
At 24 h after transfection, 1×10 6 U251 cells were injected into the right cerebral hemisphere of 5-week-old BALBc nude mice. The growth curves and tumor volumes were measured every week. The following equation was used to calculate tumor volume: tumor volume=length×width×0.5. At 5 weeks after injection, the tumors were harvested and weighed.
Ki-67 staining assays
Xenograft tumors were fixed in 10% formalin and paraffinembedded. Next, 2-µm sections were deparaffinized and subjected to antigen retrieval according to standard procedures. The sections were incubated with Ki-67 (clone MIB-1; Dako; dilution 1: 100) for 30 min. Then, the sections were incubated with secondary antibodies and visualized with 3, 3'-diaminobenzidine. Ki-67 immunoreactivity was evaluated using a labeling index (% of positive cells). Plasmid construction and dual-luciferase activity assay
The fragments of the circ-CFH sequence containing the miR binding site or mutant binding sites were amplified by PCR. Then, the fragments were cloned into a luciferase vector psi-CHECK (Promega, Madison, USA) and named circCFH wild-type or circCFH mutant. For dual-luciferase activity assays, U251 or U373 cells were seeded in 24-well plates and co-transfected with circCFH wild-type or circCFH mutant and miRNA mimics. Luciferase activity was detected 48 h after transfections by the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocols.
Statistical analysis
The data from this study are all presented as the mean ±SEM, and GraphPad (Ver. Prism 7, GraphPad Prism Software, La Jolla, CA, USA) was used for statistical analyses. The data were subjected to one-way analysis of variance, followed by comparison using the t test to evaluate the differences between the means. A *p value less than 0.05 was considered as statistically significant.
Results
The expression of circCFH was upregulated in glioma 5707 subjected to qRT-PCR. Circ-CFH was not degraded (1.00±0.11 vs. 0.89±0.09), whereas GAPDH (a linear RNA) was reduced by RNase R treatment (1.00±0.12 vs. 0.21±0.03, Figure 1B ). These results validated the circular structure of circ-CFH. Moreover, we analyzed the expression of circ-CFH in 31 pairs of human tumors compared to their adjacent normal tissues; qRT-PCR results showed that the expression in 80% of the tumor tissues was notably upregulated ( Figure 1C) . A scatter map indicated that the different expression levels of circ-CFH in the gliomas tissues and paired adjacent normal tissue were statistically significant (2.03±0.85 vs. 0.34±1.41, Figure 1D ). In addition, the circ-CFH expression was significantly upregulated in grade I-II gliomas vs. grade III-IV gliomas (2.32±0.79 vs. 1.41±0.36, Figure 1E) ; therefore, circ-CFH expression may be correlated with tumor grade (* P<0.05, Figure 1B, 1D, 1E ).
Circular RNA circ-CFH promoted glioma progression
Because circ-CFH was upregulated in gliomas, we next investigated the effect of circ-CFH on glioma cells. Figure 2B , 2C). Similarly, transfection with siCircCFH also significantly inhibited the colony formation ability and decreased the numbers of colonies formed on the plates (* P<0.05, Figure 2D siCircCFH group was significantly lower than that in the siNC group (* P<0.05, Figure 2G ). Taken together, these findings indicate that circ-CFH promoted glioma progression.
Circ-CFH functions as a miRNA sponge for miR-149 in glioma cells
Because circRNA could bind to miRNA and act as a miRNA sponge, we next studied whether circ-CFH could bind miRNA. According to a circular RNA interactome bio-informatic analysis, 4 miRNAs (miR-145, miR-149, miR-155, and miR-183) shared a binding site with circ-CFH ( Figure 3A ). To confirm whether these miRNAs can directly bind with circRNA-CFH, dual-luciferase assays were performed. U251 and U373 cells were co-transfected with each miRNA mimic and the circ-CFH wild-type reporter or circ-CFH mutant reporter. The data showed that luciferase intensity was not significantly different between the circ-CFH wild-type group and the circ-CFH mutant group when the miR-145, miR-155, and miR-183 mimics were transfected. However, the co-transfection of miR-149 mimics and the circ-CFH wild-type reporter inhibited the luciferase activity, and this reduction was not present in the circ-CFH mutant reporter group (* P<0.05, Figure 3B , 3C). These results indicated that circRNA-CFH specifically interacts with miR-149 and may serve as a sponge in U251 and U373 cells. Figure 3D , 3E). These results indicate that circ-CFH promotes glioma progression by sponging miR-149.
AKT1 is a direct target of miR-149 and is positively regulated by circ-CFH
We have shown that circ-CFH can directly bind to miR-149 and act as a sponge, so we next determined whether circ-CFH could regulate miR-149 target genes. A TargetScan analysis indicated that AKT1, FOXM1, and LRIG2 were the predicted targets of miR-149, and the putative binding sites between them are shown ( Figure 4A ). Figure 4B-4D) . A correlation analysis confirmed that circ-CFH and AKT1 expression were inversely correlated with miR-149 (r=-0.8444, Figure 4E ; r=-0.6709, Figure 4F ), while circ-CFH expression was positively correlated with AKT1 expression (r=0.8746, Figure 4G ). These results indicated that circ-CFH can regulate AKT1 by sponging miR-149.
Discussion
In the past decade, RNA sequencing and mapping have revealed that thousands of expressed genes also differentially generate circular RNAs by back-splicing or lariat introns [17] . These RNAs may not translate into proteins, but are stable and contain exons. Many of these circRNAs are dysregulated in various diseases, suggesting their involvement in disease development and progression [46] . Regarding their high conservation, stability, and relatively tissue-specific expression patterns, they could act as novel biomarkers for cancer [46] . Glioma is the most common malignant nervous system tumor and is characterized by high fatality rates and poor prognosis. Some endogenous circRNAs involved in glioma have been researched; these include TTBK2 circular RNA and cZNF292 circular RNA [47, 48] . In our study, we identified a novel circRNA in glioma; our findings may provide important evidence for circular RNA research in glioma carcinoma.
The complement factor H (CFH) gene encodes for complement factor H, which is a complement regulator and has an important role in inhibiting complement activation and inflammation [49] . In our study, we found that a CFH circRNA could arise from CFH exons and be generated by back-splicing. Circ-CFH contains 3 exons and is resistant to RNase R. However, the function of circ-CFH in glioma was unknown. We found that circ-CFH was upregulated in glioma tissues and cell lines, and its expression level was also correlated with tumor grade. Then, we explored the specific role of circ-CFH in glioma. The results indicated that circ-CFH functions as an oncogene in glioma tumorigenesis. To the best of our knowledge, this is the first study to identify the expression and functional role of circ-CFH in glioma. 
5710
Previous studies have revealed that miR-149 increased apoptosis in neuroblastoma cells, and the blockage of miR-149 promoted tumors in prostate carcinoma [50, 51] . In addition, other studies found that miR-149 decreased cell proliferation by targeting FOXM1 [52] . In glioma cells, it was also reported that miR-149 can inhibit invasiveness through blocking AKT1 signaling [53] . In our study, we confirmed a new regulation aids, circ-CFH/miR-149/Akt1, in glioma cell tumorigenesis. These results are an extension of miR-149 research in glioma. This axis also serves as solid evidence that circRNA/miRNA/mRNA regulatory systems play important physiological functions in various diseases.
